Literature DB >> 1455882

Optimization of isolated hyperthermic limb perfusion.

G Omlor1, G Gross, K W Ecker, I Burger, G Feifel.   

Abstract

During isolated limb perfusion, we studied the impact of limb temperature on the concentration of cytostatic drugs in the tissue to identify a possible selective absorption of cytostatic agents by the various tissues. Ten consecutive patients with malignant melanoma were randomly divided into two different groups and perfused with 1 mg cisplatin per kg body weight. In one group the cytostatic agents were injected under hyperthermic conditions (39.5 degrees C) and in the other group under normothermic conditions (37 degrees C). The platinum concentration in the melanoma was twice as high in the hyperthermic group as in the group under normothermic conditions. In the tumor-free tissue the platinum concentration decreased with temperature while it remained constant in the musculature. This selective concentration of cisplatin in the tumor under hyperthermic conditions is accompanied by fewer side effects. Follow-up will show whether the oncological results will be improved in the hyperthermic conditions as one might expect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455882     DOI: 10.1007/bf02067073

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  13 in total

1.  Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit.

Authors:  O CREECH; E T KREMENTZ; R F RYAN; J N WINBLAD
Journal:  Ann Surg       Date:  1958-10       Impact factor: 12.969

2.  Hyperthermic perfusion with chemotherapy for melanoma of the extremities.

Authors:  F Ghussen; I Krüger; R V Smalley; W Groth
Journal:  World J Surg       Date:  1989 Sep-Oct       Impact factor: 3.352

3.  Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities.

Authors:  R F Pommier; H S Moseley; J Cohen; C S Huang; R Townsend; W S Fletcher
Journal:  Am J Surg       Date:  1988-05       Impact factor: 2.565

4.  Lucy Wortham James lecture. Regional perfusion. Current sophistication, what next?

Authors:  E T Krementz
Journal:  Cancer       Date:  1986-02-01       Impact factor: 6.860

5.  Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future.

Authors:  B B Kroon
Journal:  Eur J Surg Oncol       Date:  1988-04       Impact factor: 4.424

6.  Impact of regional chemotherapy for melanoma metastases.

Authors:  H Voigt
Journal:  Anticancer Res       Date:  1988 May-Jun       Impact factor: 2.480

7.  An accurate method for cytostatic dosimetry in isolation perfusion based on limb vascular volume determination.

Authors:  F J Lejeune; G E Ghanem; D Liénard; P Ewalenko
Journal:  Antibiot Chemother (1971)       Date:  1988

8.  Hyperthermic perfusion with chemotherapy for cancers of the extremities.

Authors:  J S Stehlin
Journal:  Surg Gynecol Obstet       Date:  1969-08

9.  [Hyperthermic isolation perfusion of the extremities in malignant melanomas and soft tissue sarcomas].

Authors:  J Tonak; W Hohenberger; J Göhl
Journal:  Chirurg       Date:  1984-08       Impact factor: 0.955

10.  Normal tissue and solid tumor effects of hyperthermia in animal models and clinical trials.

Authors:  F K Storm; W H Harrison; R S Elliott; D L Morton
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

View more
  2 in total

Review 1.  Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.

Authors:  A M Eggermont; T L ten Hagen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

2.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.

Authors:  J H de Wilt; E R Manusama; S T van Tiel; M G van Ijken; T L ten Hagen; A M Eggermont
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.